Fritextsökning
Artiklar per år
Innehållstyper
-
DTU Nanotech får ny toppchef
Mogens Rysholt Poulsen har utnämnts till direktör för Danmarks största institut för mikro- och nanoteknologi.
-
Genjägare får ny vd
Det norska tjänsteföretaget Hunt Biosciences har utsett en ny vd.
-
Scanbalt får ny medlem
Polska Biobaltica är det senaste tillskottet i paraplyorganisationen Scanbalt.
-
Ny hövding till Roche
Roche har utsett en efterträdare till nypensionerade Curt Collin på posten som chef för External Affairs.
-
Nytt samarbete ska locka hem forskare
Turku Science Park och Nordic-Baltic Expats Forum har tecknat ett avtal för att locka fler partners till webbcommunityn. Ett av målen är att stärka yrkesnätverken inom och utanför Öresundsregionen.
-
Hallå där, Christel Fenge !
...VD i nya bolaget Recipharm Biologics, som nu i eftermiddag har ovanligt många gäster i lokalerna i Södertälje.
-
Född: ny finsk skogsforskningsjätte
Ett av europas största forskningslaboratorier slås ihop med ett av världens största skogsforskningsinstitut. Tillsammans ska de bli ett av världens främsta kompetenscentra inom skog.
-
KI-forskare får femårig forskningsprofessur
Torsten och Ragnar Söderbergs stiftelser ger Christer Betsholtz möjlighet att i fem år heltidsforska om tillväxtfaktorers roll i cancer
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Grönt ljus för Getinges bolagsköp
Medicinteknikföretaget Getinge har fått godkännande från den amerikanska konkurrensmyndigheten Federal Trade Commission, FTC för köpet av bolaget Datascope Corp. Efter klartecken från amerikanska myndigheter kan den segdragna affären nu slutföras.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
BREAKING